Regeneron : REGN

All Regeneron Articles

248 Articles

Chris Lange | Sep 27, 2018 at 4:08 PM EDT

Thursday’s Biggest Winners and Losers in the S&P 500

Thursday was a positive day for the broad U.S. markets. All three major indices recovered handily from Wednesday’s drop. Crude…

Lee Jackson | Sep 27, 2018 at 8:35 AM EDT

Merrill Lynch Loves Large Cap Biotech: 4 Top Stocks to Buy Now

Merrill Lynch recently highlighted sectors it considers a good opportunity now that are likely to outperform in the near term,…

Chris Lange | Aug 16, 2018 at 12:55 PM EDT

New Osteoarthritis Treatment Could Precipitate Another Blockbuster Drug

Teva and Regeneron both saw handy gains on Thursday after the companies posted positive topline results from their late-stage trial…

Chris Lange | Aug 15, 2018 at 9:35 AM EDT

What the FDA Has to Say About Regeneron’s Eylea

Regeneron Pharmaceuticals is facing some difficulty after it received an update from the FDA on Eylea (aflibercept) Injection in patients…

Lee Jackson | Jun 1, 2018 at 10:30 AM EDT

Biotech and Pharmaceutical Giants Go All In With Big Data Analytics

It’s no surprise that it was only a matter of time before the usage and storage of big data and…

Chris Lange | May 11, 2018 at 4:08 PM EDT

Friday’s Biggest Winners and Losers in the S&P 500

Friday was a relatively positive day for the broad U.S. markets. Although crude oil backed off, it is still holding…

Jon C. Ogg | May 1, 2018 at 12:15 PM EDT

Will a PCSK9 Inhibitor Price Cut Help Drive Lowering LDL-Cholesterol Drug Use?

Regeneron Pharmaceuticals and Sanofi are committing to lowering the price of the anti-cholesterol drug Praluent.

Jon C. Ogg | Apr 17, 2018 at 11:35 AM EDT

Will a Recent Rheumatoid Arthritis Drug Approval See Rekindled Interest?

Rheumatoid arthritis is an autoimmune disease that attacks tissues within the joints, and it is a major target of U.S.…

Jon C. Ogg | Apr 9, 2018 at 9:00 AM EDT

Top Analyst Upgrades and Downgrades: Alcoa, Cemex, Comerica, Facebook, GM, Incyte, Proofpoint, Regeneron and More

The top analyst upgrades, downgrades and other research calls from Monday include Alcoa, CEMEX, Comerica, Facebook, General Motors, Incyte, Proofpoint…

Lee Jackson | Mar 1, 2018 at 8:10 AM EST

10 Large Cap Stocks the Top Hedge Funds Are Buying Now

While chasing what portfolio managers own isn’t always the best idea, many people have made a lot of money by…

Jon C. Ogg | Feb 21, 2018 at 9:14 AM EST

Top Analyst Upgrades and Downgrades: Capital One, Domino’s, Home Depot, Mosaic, Regenron, Six Flags, US Steel, Walmart and More

The top analyst upgrades, downgrades and other research calls from Wednesday include Capital One, Domino's, Home Depot, Mosaic, Regenron, Six…

Jon C. Ogg | Dec 28, 2017 at 9:15 AM EST

Top Analyst Upgrades and Downgrades: Amex, Cellectis, ForeScout, Mastercard, Mueller Water, PG&E, Party City, Regeneron, Visa and More

The include American Express, Cellectis, ForeScout Technologies, Mastercard, Mueller Water, PG&E, Party City, Regeneron Pharmaceuticals and Visa.

Lee Jackson | Dec 11, 2017 at 9:50 AM EST

4 Large Cap Biotech Leaders Are Huge Tax Reform Winners

One industry that could be a huge winner from tax reform, and may surprise some investors, is biotechnology, especially for…

Jon C. Ogg | Dec 6, 2017 at 10:05 AM EST

2018 Outlook: Biotech Stocks Looking Strong for Value and Growth Investors

It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately,…

Jon C. Ogg | Oct 20, 2017 at 9:05 AM EDT

Top Analyst Upgrades and Downgrades: Baidu, Barclays, Celgene, HPE, Intel, Kimberly-Clark, Lululemon, PayPal, Stratasys and More

The top analyst upgrades, downgrades and other research calls from Friday include Baidu, Barclays, Celgene, HPE, Intel, Kimberly-Clark, Lululemon, PayPal…

1 … 6 7 8 9 10 … 17

Regeneron : REGN

All Regeneron Articles

Thursday’s Biggest Winners and Losers in the S&P 500

Merrill Lynch Loves Large Cap Biotech: 4 Top Stocks to Buy Now

New Osteoarthritis Treatment Could Precipitate Another Blockbuster Drug

What the FDA Has to Say About Regeneron’s Eylea

Biotech and Pharmaceutical Giants Go All In With Big Data Analytics

Friday’s Biggest Winners and Losers in the S&P 500

Will a PCSK9 Inhibitor Price Cut Help Drive Lowering LDL-Cholesterol Drug Use?

Will a Recent Rheumatoid Arthritis Drug Approval See Rekindled Interest?

Top Analyst Upgrades and Downgrades: Alcoa, Cemex, Comerica, Facebook, GM, Incyte, Proofpoint, Regeneron and More

10 Large Cap Stocks the Top Hedge Funds Are Buying Now

Top Analyst Upgrades and Downgrades: Capital One, Domino’s, Home Depot, Mosaic, Regenron, Six Flags, US Steel, Walmart and More

Top Analyst Upgrades and Downgrades: Amex, Cellectis, ForeScout, Mastercard, Mueller Water, PG&E, Party City, Regeneron, Visa and More

4 Large Cap Biotech Leaders Are Huge Tax Reform Winners

2018 Outlook: Biotech Stocks Looking Strong for Value and Growth Investors

Top Analyst Upgrades and Downgrades: Baidu, Barclays, Celgene, HPE, Intel, Kimberly-Clark, Lululemon, PayPal, Stratasys and More

One Power-Line Settlement Paid Him Three Ways. Social Security Counted Only the Lost Harvest.

Up 113% In 12 Months, How High Can CAT Stock Soar?

Cerebras, Intel, and AMD Shares Fall Ahead of Tonight’s ‘Supernova’ Event

One Power-Line Settlement Paid Him Three Ways. Social Security Counted Only the Lost Harvest.

At 63, His Sick-Pay Checks Kept Coming. After Six Months, Social Security Tax Stopped.

15 Coins That Look Ordinary but Are Worth a Small Fortune

One Power-Line Settlement Paid Him Three Ways. Social Security Counted Only the Lost Harvest.

Regeneron : REGN

All Regeneron Articles

Thursday’s Biggest Winners and Losers in the S&P 500

Merrill Lynch Loves Large Cap Biotech: 4 Top Stocks to Buy Now

New Osteoarthritis Treatment Could Precipitate Another Blockbuster Drug

What the FDA Has to Say About Regeneron’s Eylea

Biotech and Pharmaceutical Giants Go All In With Big Data Analytics

Friday’s Biggest Winners and Losers in the S&P 500

Will a PCSK9 Inhibitor Price Cut Help Drive Lowering LDL-Cholesterol Drug Use?

Will a Recent Rheumatoid Arthritis Drug Approval See Rekindled Interest?

Top Analyst Upgrades and Downgrades: Alcoa, Cemex, Comerica, Facebook, GM, Incyte, Proofpoint, Regeneron and More

10 Large Cap Stocks the Top Hedge Funds Are Buying Now

Top Analyst Upgrades and Downgrades: Capital One, Domino’s, Home Depot, Mosaic, Regenron, Six Flags, US Steel, Walmart and More

Top Analyst Upgrades and Downgrades: Amex, Cellectis, ForeScout, Mastercard, Mueller Water, PG&E, Party City, Regeneron, Visa and More

4 Large Cap Biotech Leaders Are Huge Tax Reform Winners

2018 Outlook: Biotech Stocks Looking Strong for Value and Growth Investors

Top Analyst Upgrades and Downgrades: Baidu, Barclays, Celgene, HPE, Intel, Kimberly-Clark, Lululemon, PayPal, Stratasys and More

One Power-Line Settlement Paid Him Three Ways. Social Security Counted Only the Lost Harvest.

Up 113% In 12 Months, How High Can CAT Stock Soar?

Cerebras, Intel, and AMD Shares Fall Ahead of Tonight’s ‘Supernova’ Event

Featured Reads

One Power-Line Settlement Paid Him Three Ways. Social Security Counted Only the Lost Harvest.

At 63, His Sick-Pay Checks Kept Coming. After Six Months, Social Security Tax Stopped.